Biocorp (ALCOR.PA) Fundamental Analysis & Valuation

EPA:ALCOR • FR0012788065

Current stock price

35.1 EUR
+0.1 (+0.29%)
Last:

This ALCOR.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ALCOR.PA Profitability Analysis

1.1 Basic Checks

  • ALCOR had negative earnings in the past year.
  • ALCOR had a negative operating cash flow in the past year.
ALCOR.PA Yearly Net Income VS EBIT VS OCF VS FCFALCOR.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -2M -4M -6M

1.2 Ratios

  • ALCOR's Return On Assets of -5.17% is in line compared to the rest of the industry. ALCOR outperforms 43.86% of its industry peers.
  • Looking at the Return On Equity, with a value of -26.47%, ALCOR is doing worse than 70.18% of the companies in the same industry.
Industry RankSector Rank
ROA -5.17%
ROE -26.47%
ROIC N/A
ROA(3y)-4.34%
ROA(5y)-20.65%
ROE(3y)-20.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALCOR.PA Yearly ROA, ROE, ROICALCOR.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 1K 2K 3K

1.3 Margins

  • ALCOR's Gross Margin of 91.16% is amongst the best of the industry. ALCOR outperforms 94.74% of its industry peers.
  • ALCOR's Gross Margin has been stable in the last couple of years.
  • ALCOR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.6%
GM growth 5Y-0.01%
ALCOR.PA Yearly Profit, Operating, Gross MarginsALCOR.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 100 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ALCOR.PA Health Analysis

2.1 Basic Checks

  • ALCOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ALCOR has been increased compared to 1 year ago.
  • Compared to 1 year ago, ALCOR has a worse debt to assets ratio.
ALCOR.PA Yearly Shares OutstandingALCOR.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M
ALCOR.PA Yearly Total Debt VS Total AssetsALCOR.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M

2.2 Solvency

  • An Altman-Z score of 10.15 indicates that ALCOR is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of ALCOR (10.15) is better than 92.98% of its industry peers.
  • ALCOR has a Debt/Equity ratio of 1.95. This is a high value indicating a heavy dependency on external financing.
  • ALCOR's Debt to Equity ratio of 1.95 is on the low side compared to the rest of the industry. ALCOR is outperformed by 84.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.95
Debt/FCF N/A
Altman-Z 10.15
ROIC/WACCN/A
WACC7.63%
ALCOR.PA Yearly LT Debt VS Equity VS FCFALCOR.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 2M -2M 4M -4M 6M

2.3 Liquidity

  • ALCOR has a Current Ratio of 1.63. This is a normal value and indicates that ALCOR is financially healthy and should not expect problems in meeting its short term obligations.
  • ALCOR's Current ratio of 1.63 is in line compared to the rest of the industry. ALCOR outperforms 42.11% of its industry peers.
  • ALCOR has a Quick Ratio of 1.34. This is a normal value and indicates that ALCOR is financially healthy and should not expect problems in meeting its short term obligations.
  • ALCOR's Quick ratio of 1.34 is in line compared to the rest of the industry. ALCOR outperforms 59.65% of its industry peers.
Industry RankSector Rank
Current Ratio 1.63
Quick Ratio 1.34
ALCOR.PA Yearly Current Assets VS Current LiabilitesALCOR.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ALCOR.PA Growth Analysis

3.1 Past

  • The earnings per share for ALCOR have decreased strongly by -318.01% in the last year.
  • Looking at the last year, ALCOR shows a quite strong growth in Revenue. The Revenue has grown by 14.13% in the last year.
  • The Revenue has been growing by 38.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-318.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.31%
Revenue 1Y (TTM)14.13%
Revenue growth 3Y11.37%
Revenue growth 5Y38.13%
Sales Q2Q%30.55%

3.2 Future

  • ALCOR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 148.12% yearly.
  • Based on estimates for the next years, ALCOR will show a very strong growth in Revenue. The Revenue will grow by 31.93% on average per year.
EPS Next Y-96.7%
EPS Next 2Y8.94%
EPS Next 3Y39.3%
EPS Next 5Y148.12%
Revenue Next Year15.99%
Revenue Next 2Y32.35%
Revenue Next 3Y31.93%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ALCOR.PA Yearly Revenue VS EstimatesALCOR.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
ALCOR.PA Yearly EPS VS EstimatesALCOR.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2020 2021 2022 2023 2024 2025 2026 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. ALCOR.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALCOR. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 3407.77, which means the current valuation is very expensive for ALCOR.
  • The rest of the industry has a similar Price/Forward Earnings ratio as ALCOR.
  • ALCOR's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 38.16.
Industry RankSector Rank
PE N/A
Fwd PE 3407.77
ALCOR.PA Price Earnings VS Forward Price EarningsALCOR.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 1K 2K 3K

4.2 Price Multiples

  • ALCOR's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1183.44
ALCOR.PA Per share dataALCOR.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALCOR's earnings are expected to grow with 39.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.94%
EPS Next 3Y39.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALCOR.PA Dividend Analysis

5.1 Amount

  • ALCOR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ALCOR.PA Fundamentals: All Metrics, Ratios and Statistics

Biocorp

EPA:ALCOR (9/27/2023, 7:00:00 PM)

35.1

+0.1 (+0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap154.53M
Revenue(TTM)11.67M
Net Income(TTM)-651.18K
Analysts84
Price Target35.96 (2.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-92.31%
EPS NY rev (3m)-97.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-13.53%
Revenue NY rev (3m)-17.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3407.77
P/S 13.24
P/FCF N/A
P/OCF N/A
P/B 62.8
P/tB 63.85
EV/EBITDA 1183.44
EPS(TTM)-0.15
EYN/A
EPS(NY)0.01
Fwd EY0.03%
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS2.65
BVpS0.56
TBVpS0.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -5.17%
ROE -26.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.16%
FCFM N/A
ROA(3y)-4.34%
ROA(5y)-20.65%
ROE(3y)-20.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.6%
GM growth 5Y-0.01%
F-Score2
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 1.95
Debt/FCF N/A
Debt/EBITDA 35.95
Cap/Depr 111.48%
Cap/Sales 8.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.63
Quick Ratio 1.34
Altman-Z 10.15
F-Score2
WACC7.63%
ROIC/WACCN/A
Cap/Depr(3y)202.11%
Cap/Depr(5y)158.59%
Cap/Sales(3y)15.6%
Cap/Sales(5y)13.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-318.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.31%
EPS Next Y-96.7%
EPS Next 2Y8.94%
EPS Next 3Y39.3%
EPS Next 5Y148.12%
Revenue 1Y (TTM)14.13%
Revenue growth 3Y11.37%
Revenue growth 5Y38.13%
Sales Q2Q%30.55%
Revenue Next Year15.99%
Revenue Next 2Y32.35%
Revenue Next 3Y31.93%
Revenue Next 5YN/A
EBIT growth 1Y-632.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year209.11%
EBIT Next 3Y106.34%
EBIT Next 5YN/A
FCF growth 1Y18.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.61%
OCF growth 3YN/A
OCF growth 5YN/A

Biocorp / ALCOR.PA Fundamental Analysis FAQ

What is the fundamental rating for ALCOR stock?

ChartMill assigns a fundamental rating of 3 / 10 to ALCOR.PA.


What is the valuation status for ALCOR stock?

ChartMill assigns a valuation rating of 1 / 10 to Biocorp (ALCOR.PA). This can be considered as Overvalued.


How profitable is Biocorp (ALCOR.PA) stock?

Biocorp (ALCOR.PA) has a profitability rating of 2 / 10.


What is the financial health of Biocorp (ALCOR.PA) stock?

The financial health rating of Biocorp (ALCOR.PA) is 3 / 10.